반응식
[CH3:1][O:2][C:3]1[CH:8]=[CH:7][C:6]([CH2:9][CH2:10][NH2:11])=[CH:5][CH:4]=1.[CH2:12]([O:14][C:15]([C:17]1[C:18](=[O:40])[C:19]2[CH:24]=[N:23][C:22](S(C)(=O)=O)=[N:21][C:20]=2[N:29]([C:31]2[CH:32]=[C:33]3[C:37](=[CH:38][CH:39]=2)[CH2:36][CH2:35][CH2:34]3)[CH:30]=1)=[O:16])[CH3:13]>>[CH2:12]([O:14][C:15]([C:17]1[C:18](=[O:40])[C:19]2[CH:24]=[N:23][C:22]([NH:11][CH2:10][CH2:9][C:6]3[CH:7]=[CH:8][C:3]([O:2][CH3:1])=[CH:4][CH:5]=3)=[N:21][C:20]=2[N:29]([C:31]2[CH:32]=[C:33]3[C:37](=[CH:38][CH:39]=2)[CH2:36][CH2:35][CH2:34]3)[CH:30]=1)=[O:16])[CH3:13]참가 물질
3
실험 절차
Using the procedure outlined in Example 1 Step F, the title compound was prepared 2-(4-methoxyphenyl)-ethylamine and 8-indan-5-yl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 1 Step E, 20 mg, 0.04 mmol). 19 mg of 8-Indan-5-yl-2-[2-(4-methoxy-phenyl)-ethylamino]-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester was obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ (ppm): 9.23 (s, 1H), 8.47 (s, 1H), 7.37 (d, J=7.8 Hz, 1H), 7.26 (s, 1H), 7.18 (d, J=7.8 Hz, 1H), 6.81 (d, J=8.6 Hz, 2H), 6.77 (d, J=8.6 Hz, 2H), 5.84 (br, 1H), 4.37 (q, J=7.1 Hz, 2H), 3.78 (s, 3H), 3.34 (m, 2H), 3.00 (m, 7H), 2.64 (t, J=7.2 Hz, 2H), 2.18 (m, 2H), 1.38 (t, J=7.1 Hz, 3H).
출처 및 근거
- ORD 기록
- ord-1b855d8e9b0c46178a8fa3663c80ab40
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07728003B2
연결된 노트
불러오는 중…